Primary Spinal Cord Oligodendroglioma with Postoperative Adjuvant Radiotherapy: A Case Report

Woon Tak Yuh¹, Chun Kee Chung¹, Sung-Hye Park²

Departments of ¹Neurosurgery and ²Pathology, Seoul National University College of Medicine, Seoul, Korea

Primary spinal cord oligodendrogliomas are rare tumors comprising two percent of all spinal cord tumors. Although a treatment guideline has yet to be established, maximal surgical resection is primary in the treatment of spinal cord oligodendrogliomas. Adjuvant radiotherapy has remained controversial, and it is unclear whether chemotherapy adds any benefit. In this case report, the authors present a 24-year-old male who had a seven-year history of left leg weakness and a radiating pain in both legs. Magnetic resonance image (MRI) showed an intramedullary mass at the T4-T8 level. He underwent subtotal removal of the tumor and pathologic diagnosis revealed a WHO grade II oligodendroglioma. The patient was treated with radiotherapy postoperatively and followed up with MRI annually. Clinical and radiological status of the patient had been stationary for four years after the surgery. The five-year follow-up MRI showed an increase in the size and extent of the residual tumor. Despite radiological progression, considering that symptoms and the performance status of the patient had remained unchanged, further treatment has not been performed. Given the clinical outcome of this patient, close observation after subtotal removal with adjuvant radiotherapy is one of the acceptable treatment options for WHO grade II spinal cord oligodendrogliomas.

Key Words: Oligodendroglioma · Spinal cord neoplasm · Radiotherapy · Chromosome 1p/19q co-deletion · MGMT gene promoter methylation

INTRODUCTION

Primary spinal cord oligodendrogliomas are very rare tumors, comprising only two percent of all spinal cord tumors². The overall prognosis with regard to oligodendrogliomas of spinal cord is apparently worse than that of low-grade astrocytomas⁴. For intracranial WHO grade II oligodendrogliomas, maximal safe surgical resection followed by adjuvant radiotherapy is the standard treatment⁷,¹¹). However, in the case of spinal cord oligodendrogliomas, there is no uniform treatment guideline. Maximal safe surgical resection of the tumor is the standard treatment, but adjuvant radiotherapy has remained controversial⁹. In the present case, we report a patient with WHO grade II spinal cord oligodendroglioma who underwent subtotal tumor removal and adjuvant radiotherapy with good functional outcome and disease control.

CASE REPORT

1. History

A 29-year-old male presented with a seven-year history of left leg weakness and a radiating pain in both legs. His past medical and family history was unremarkable. He visited a local primary clinic and was diagnosed with a herniated lumbar intervertebral disc. Physical therapy was performed but was not effective. As his symptoms had worsened gradually, in 2007, he was referred to a local neurosurgery clinic. Cervical and thoracic magnetic resonance image (MRI) was performed and revealed a fusiform weakly enhancing mass ranging from the T4 to T8 level with associated hydrosyrinx. The patient was referred to the neurosurgery department at our institution.

2. Examination

A physical examination revealed muscle weakness of grade 4/5 in the left lower extremity, which resulted in a mild gait disturbance, a radiating pain in the bilateral lower extremity, hypesthesia below the umbilical level, deep tendon hyperreflexia of the bilateral ankle and knee, and bilateral ankle clonus. No urinary symptoms were observed. The MRI performed
outside showed a large intramedullary fusiform mass ranging from the T4 to T8 level with associated hydrosyrrinx ranging from the T2 to T4 level. The mass was isointense on T1-weighted images (WI) (Fig. 1A) and slightly hyperintense on T2WI with a relatively good demarcated margin (Fig. 1C). On postgadolinium images, focal weak heterogeneous enhancement was noted at the upper part of the tumor (Fig. 1B). Computed tomography (CT) was also performed and showed calcification in the center of the tumor (Fig. 1D).

3. Operation

The patient underwent a T3-T9 laminectomy. Intraoperatively, a tense dura was found. After vertical incision of the dura, an edematous and hypervascularized spinal cord was exposed with midline effacement (Fig. 1E). Midline myelotomy from T3 to T8 was performed with an ophthalmic knife, scissors and dissectors, which revealed grayish, gelatinous and firm tumor tissue. The hydrosyrrinx was opened during an exploration of the T3-level spinal cord, which resulted in a sunken spinal cord below the T4 level. A plane between the spinal cord and the tumor was developed from the superior aspect of the tumor at the T4 level using microsurgical techniques. The tumor was difficult to distinguish from the cord, and the plane was indistinct. An intraoperative frozen tissue biopsy led to a diagnosis of a low-grade glioma rather than a gangliogenic tumor or an ependymoma. Due to poor demarcation between the tumor and the spinal cord, the tumor was subtotally removed by internal debulking using a Cavitron ultrasonic surgical aspirator. Meticulous hemostasis was accomplished. Without closure of the pial layer, dura edges were approximated with a watertight closure with an artificial dura. After saline irrigation, the surgical wound was closed in anatomical layers.

4. Histological Findings

The histopathological examination represented a highly cellular tumor with dysmorphic calcification, prominent hyalinized blood vessels and Rosenthal fibers in the periphery of the tumor. There was no vascular endothelium hypoplasia or necrosis. The permanent sections of this tumor showed the classic pattern of low cellular monotonous round cells with a clear cytoplasm upon hematoxylin and eosin (H&E) staining (Fig 2A). The immunohistochemistry of the glial fibrillary acidic protein (GFAP) revealed that most cells were negative, with some positive reactive astrocytes (Fig 2B). Other immunohistochemistry stains for Galectin-3, Neu-N, synaptophysin and CD99 were positive, while p53, EGFR and neuron-specific enolase (NSE) were negative. The Ki-67 labeling index was less than 1% (Fig 2C). A molecular pathologic examination by fluorescence in situ hybridization (FISH) revealed no codeletion of chromosomes 1p and 19q. Another molecular examination of O6-methylguanine-DNA methyltransferase (MGMT) gene promoter methylation by polymerase chain reaction (PCR) was performed and was found to be positive. The final pathological diagnosis was a low-grade glioma, most likely a WHO grade II oligodendroglioma.
5. Postoperative Course

Immediate postoperatively, the motor power of the lower limbs remained unchanged at grade 4/5, and paresthesia was improved slightly. However, hypesthesia was newly developed with worsened spasticity and hyperreflexia. With a thoracolumbosacral orthosis, the patient was able to walk with a cane. After two weeks of rehabilitation, the patient recovered to his preoperative condition and was discharged. The residual tumor was treated with radical radiotherapy at 45 Gy administered in 25 fractions over five weeks, starting one month after the operation. Since the adjuvant radiotherapy, MRI has been performed annually, showing no significant interval change in the size, extent and enhancement pattern of the residual tumor during the initial four-year postoperative period. A postoperative five-year follow-up MRI revealed an increase in the size and extent of the residual tumor with cystic change and focal gadolinium enhancement (Fig. 3). In spite of the radiological progression of the tumor, there were no changes in symptoms or performance status. Therefore, the patient is on close observation with follow up through MRI annually without any additional treatment.

DISCUSSION

Primary oligodendrogliomas of the spinal cord are rare and represent 2% of all tumors arising from the spinal cord and its terminal and 1.59% of all oligodendrogliomas. Since the first report of a primary spinal oligodendroglioma by Kernohan et al. in 1931, including this case report only 56 cases of primary spinal cord oligodendrogliomas have been reported in the literature.

Primary oligodendrogliomas occur in both children and adults, with a mean age of 28.4 years old according to the literature review by Fountas et al. It is widely accepted that intracranial oligodendrogliomas are more common among males; however, the existent literature shows that there is no significant gender trend with regard to spinal oligodendrogliomas. By the literature, most commonly presenting symptoms are spinal pain and sensory deficit, followed by motor deficit and voiding problems, which depend on the anatomic location of the tumor. Occasionally, several case reports have revealed increased intracranial hypertension due to diffuse oligodendrogliomatosis. The most common anatomic locations of spinal oligodendrogliomas are the thoracic level, followed by the cervical, thoracocervical junction, lumbar and thora-columbar levels.

MRI is the diagnostic method of choice. Primary spinal oligodendrogliomas usually appear as heterogeneous hypointense lesions on T1WI and as hyperintense lesions on T2WI. The vast majority of spinal oligodendrogliomas demonstrate mild to moderate heterogeneous spotty enhancement on postgadolinium images. Cystic components or cystic necrotic areas may be observable, particularly in cases of high-grade spinal oligodendrogliomas. In addition to MRI, plain X-rays and CT scans can be helpful for evaluating tumor-associated skeletal deformities and instances of calcification. The presence of calcification in spinal cord oligodendrogliomas has been estimated to range from 28% to 40%. In this case, the initial MRI showed typical iso-intense lesions on T1WI and as hyper-intense lesions on T2WI, with focal heterogeneous weak enhancement. The margin of the tumor was relatively well demarcated by MRI; however, the tumor was difficult to distinguish from the normal spinal cord intraoperatively. A CT scan showed calcification in the tumor. Postoperative five-year follow-up MRI revealed an increase in lesions size and extent of the residual tumors with cystic changes and
focal enhancement, suggesting the possibility of a highgrade component as well as changes related to the radiotherapy. The classic microscopic appearance of oligodendrogliomas is an infiltrating glial neoplasm composed of monotonous clear cells with perinuclear halos, called a “fried egg” appearance, embedded in a scaffolding of “chicken wire” vessels. According to immunohistochemical analyses, spinal oligodendrogliomas generally show no expression to GFAP but occasionally reveal focal immunoreactivity due to the presence of scattered astrocytes in the tumor bed or the presence of minigemistocytes. In adult intracranial oligodendrogliomas, approximately 80% contain characteristic chromosome 1p36 and 19q13 co-deletion, which appears to correlate with chemosensitivity. In this case, immunohistochemistry on GFAP and 19q co-deletion, which appears to correlate with chemosensitivity. In this case, immunohistochemistry on GFAP and 19q co-deletion, which appears to correlate with chemosensitivity.

In this study, we report a spinal cord oligodendroglioma patient with postoperative radiotherapy and chemotherapy that the mean survival time was 28.6 months. In the present case, conditions such as a young age, a large residual WHO grade II oligodendroglioma and negative results for 1p/19q co-deletion were good indications for postoperative adjuvant radiotherapy. After radiotherapy, there was no evidence of the radiation induced complications described above until the fifth year postoperative follow-up examination.

Postoperative chemotherapy has been employed in limited cases of partially resected spinal oligodendrogliomas. McLeod et al. and Ramirez et al. reported spinal oligodendroglioma patients treated with procarbazine, lomustine, and vincristine. Guppy et al. reported a good response after administering temozolomide with concurrent local radiotherapy of 45 Gy for a spinal oligodendroglioma with co-deletion of 1p and 19q. However, these data are very limited, and chemotherapy has been considered as the only adjuvant treatment option for cases of partially resected high-grade oligodendrogliomas for which radiotherapy may have severe side effects. For the current case, there was only MGMT gene promoter methylation without chromosome 1p/19q co-deletion, which is not favorable for chemotheraphy. However, given the revealed radiological progression of the tumor after postoperative radiotherapy, additional chemotherapy can be considered as a further treatment option.

The postoperative prognosis of spinal oligodendrogliomas has been reported to be less favorable than that of low-grade intramedullary astrocytomas. Fortuna et al. reported in their review that the mean survival time was 28.6 months. In this study, we report a spinal cord oligodendroglioma patient with four years of progression-free survival, only after subtotal removal of the tumor and adjuvant radiotherapy. Despite the radiological progression of the disease, and considering that the symptoms and performance status of the patient remained unchanged, further treatment has not been performed and the patient is on close observation with annual MRI follow ups. If the performance status of the patient is aggravated or radiological progression become evident, a second operation or adjuvant chemotherapy should be considered.

**CONCLUSION**

Spinal cord primary oligodendrogliomas are rare tumors without a standard treatment guideline. Aggressive tumor removal is the most important step, but it is challenging to obtain maximal surgical resection due to the infiltrative nature of these tumors and risk of postoperative neurological deficit. Adjuvant radiotherapy and chemotherapy remain controversial. In this case, the patient underwent subtotal tumor removal followed by adjuvant radiotherapy without treatment-related
complications. During postoperative five-year follow ups without any additional treatments, the clinical status of the patient has been exceptionally stationary, only with recent radiological progression of the tumor according to an MRI exam. Therefore, we concluded that given the lack of an established treatment guideline, maximal safe resection with adjuvant radiotherapy is an acceptable treatment option for primary spinal cord WHO grade II oligodendrogliomas.

ACKNOWLEDGEMENT

This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning (2014R1A2A11049662).

This work was also supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP) (No. 2010-0028631).

REFERENCES

1. Bigner DD, McLendon RE, Bruner LM: Russell & Rubinstein’s pathology of tumors of the nervous system, ed 6. London: Arnold, pp307-571, 1998
2. Choe WJ, Chung CK, Cho BK, Kim HJ: Spinal Cord Tumors: An Analysis of 654 Cases (1973-1999). J Korean Neurosurg Soc 30:1004-1012, 2001
3. Fortuna A, Celli P, Palma L: Oligodendrogliomas of the spinal cord. Acta Neurochir (Wien) 52:305-329, 1980
4. Fountas KN, Karamapelis I, Nikolakakos LG, Troup EC, Robinson JS: Primary spinal cord oligodendroglioma: case report and review of the literature. Childs Nerv Syst 21:171-175, 2004
5. Gilmer-Hill HS, Ellis WG, Imbesi SG, Boggan JE: Spinal oligodendroglioma with gliomatosis in a child: case report. J Spine Neurosurg 92:109-113, 2000
6. Guppy KH, Akins PT, Moeys GS, Prados MD: Spinal cord oligodendroglioma with 1p and 19q deletions presenting with cerebral oligodendrogliomatosis. J Spine Neurosurg 10:337-363, 2009
7. Hayat MA: Tumors of the Central Nervous System, Volume 6: Spinal tumors. Netherlands: Springer, pp61-70, 2012
8. Kernohan JW, Woltman HW, Adson AW: Intramedullary tumors of the spinal cord: a review of fifty-one cases, with an attempt at histologic classification. Arch Neurol Psychiatry 25:679-701, 1931
9. Lundar T, Due-Tønnessen BJ, Egge A, Scheie D, Stensvold E, Brandal P: Neurosurgical treatment of oligodendrogial tumors in children and adolescents: a single-institution series of 35 consecutive patients. J Neurosurg Pediatr 12:241-246, 2013
10. Ramírez C, Delrieu O, Mineo JF, Paradot G, Allaudi M, Dubois F, et al: Intracranial dissemination of primary spinal cord anaplastic oligodendroglioma. Eur J Neurol 14:578-580, 2007
11. Shaw E, Arunsell R, Scheithauer B, O’Fallon J, O’Neill B, Dainpoli R, et al: Prospective randomized trial of low-versus high-dose radiation therapy in adults with supratentorial low-grade gliomas: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol 20:2267-2276, 2002
12. Ushida T, Sonobe H, Mizobuchi H, Toda M, Tani T, Yamamoto H: Oligodendroglioma of the “widespread” type in the spinal cord. Childs Nerv Syst 14:751-755, 1998
13. Wang F, Qiao G, Lou X: Spinal cord anaplastic oligodendroglioma with 1p deletion: report of a relapsing case treated with temozolomide. J Neurooncol 104:387-394, 2010
14. Zimmerman RA, Bilaniuk LT: Imaging of tumors of the spinal canal and cord. Radiol Clin North Am 26:965-1007, 1998